Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells

Journal of Agricultural and Food Chemistry

Volumn 61, Issue 48, 2013, Pages 11817-11824

  Chen, Wei Chih ^a   Lai, Ying An ^b   Lin, Ying Chao ^c   Ma, Jui Wen ^d   Huang, Li Fen ^e   Yang, Ning Sun ^f   Ho, Chi Tang ^g   Kuo, Sheng Chu ^b   Way, Tzong Der ^b,d,h  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e YUAN ZE UNIVERSITY   (Taiwan)

^f AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^g RUTGERS UNIVERSITY   (United States)

^h ASIA UNIVERSITY   (Taiwan)

Author keywords

curcumin; doxorubicin; epithelial and mesenchymal transition; Triple negative breast cancer

Indexed keywords

ANTIPROLIFERATIVE EFFECT; CURCUMIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL AND MESENCHYMAL TRANSITION; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSFORMING GROWTH FACTORS; TRIPLE-NEGATIVE BREAST CANCERS;

CHEMOTHERAPY; DISEASES;

SIGNALING;

CURCUMIN; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA;

BREAST TUMOR; CELL PROLIFERATION; CONFERENCE PAPER; DOWN REGULATION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DOWN-REGULATION; DOXORUBICIN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84889769276     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf404092f     Document Type: Conference Paper

References (32)

1. Arendos, M.; Bihan, C.; Delaloge, S.; Andre, F. Triple-negative breast cancer: Are we making headway at least? Ther. Adv. Med. Oncol. 2012, 4, 195-210
2. Craig, D. W.; O'Shaughnessy, J. A.; Kiefer, J. A.; Aldrich, J.; Sinari, S.; Moses, T. M.; Wong, S.; Dinh, J.; Christoforides, A.; Blum, J. L.; Aitelli, C. L.; Osbome, C. R.; Izatt, T.; Kurdoglu, A.; Baker, A.; Koeman, J.; Barbacioru, C.; Sakarya, O.; De La Vega, F. M.; Siddiqui, A.; Hoang, L.; Billings, P. R.; Salhia, B.; Tolcher, A. W.; Trent, J. M.; Mousses, S.; Von Hoff, D.; Carpten, J. D. Genome and transcriptome sequencing in prospectiverefractory metastatic triple negative breast cancer uncoverstherapeutic vulnerabilities Mol. Cancer Ther. 2013, 12, 104-116
3. Chan, S.; Friedrichs, K.; Noel, D.; Pinter, T.; Van Belle, S.; Vorobiof, D.; Duarte, R.; Gil Gil, M.; Bodrogi, I.; Murray, E.; Yelle, L.; Von Minckwitz, G.; Korec, S.; Simmonds, P.; Buzzi, F.; Gonzalez Mancha, R.; Richardson, G.; Walpole, E.; Ronzoni, M.; Murawsky, M.; Alakl, M.; Riva, A.; Crown, J. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J. Clin. Oncol. 1999, 17, 2341-2354
4. Duggan, S. T.; Keating, G. M. Pegylated liposomal doxorubicin Drugs 2011, 71, 2531-2558
5. Alba, E.; Ruiz-Borrego, M.; Margeli, M.; Rodriguez-Lescure, A.; Sanchez-Rovira, P.; Ruiz, A.; Mel-Lorenzo, J. R.; Ramos-Vazquez, M.; Ribelles, N.; Calvo, E.; Casado, A.; Marquez, A.; Vicente, D.; Garcia-Saenz, J. A.; Martin, M. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study Breast Cancer Res. Treat. 2010, 122, 169-176
6. Ho, J. A.; Fan, N. C.; Jou, F. A.; Wu, L. C.; Sun, T. P. Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC-LIF: Liposomal carrier for enhanced drug delivery Talanta 2012, 99, 683-688
7. Li, Q. Q.; Xu, J. D.; Wang, W. J.; Cao, X. X.; Chen, Q.; Tang, F.; Chen, Z. Q.; Liu, X. P.; Xu, Z. D. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells Clin. Cancer Res. 2009, 15, 2657-2665
8. Hu, Q. D.; Chen, W.; Yan, T. L.; Ma, T.; Chen, C. L.; Liang, C.; Zhang, Q.; Xia, X. F.; Liu, H.; Zhi, X.; Zheng, X. X.; Bai, X. L.; Yu, X. Z.; Liang, T. B. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells Cancer Lett. 2012, 28, 207-213
9. Li, W.; Liu, C.; Tang, Y.; Li, H.; Zhou, F.; Lv, S. Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells Asian Pac. J. Cancer Prev. 2011, 12, 2575-2880
10. Heldin, C. H.; Landström, M.; Moustakas, A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition Curr. Opin. Cell Biol. 2009, 21, 166-176
11. Zavadil, J.; Böttinger, E. P. TGF-β and epithelial-to- mesenchymal transitions Oncogene 2005, 29, 5764-5774
12. Gavert, N.; Ben-Ze'ev, A. Epithelial-mesenchymal transition and the invasive potential of tumors Trends Mol. Mes. 2008, 14, 199-209
13. Moustakas, A.; Heldin, C. H. Induction of epithelial-mesenchymal transition by transforming growth factor β Semin. Cancer Biol. 2012, 22, 446-454
14. Medici, D.; Hay, E. D.; Olsen, B. R. Snail and Slug promote epithelial-mesenchymal transition through β-catenin-T-cell factor-4-dependent expression of transforming growth factor-β3 Mol. Biol. Cell 2008, 19, 4875-4887
15. Herencia, C.; Martínez-Moreno, J. M.; Herrera, C.; Corrales, F.; Santiago-Mora, R.; Espejo, I.; Barco, M.; Almaden, Y.; de la Mata, M.; Rodriguez-Ariza, A.; Munoz-Castaneda, J. R. Nuclear translocation of β-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype PLoS One 2012, 7 e34656
16. Yan, D.; Avtanski, D.; Saxena, N. K.; Sharma, D. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via AKT/GSK3-β and MTA1/Wnt1 protein-dependent pathways J. Biol. Chem. 2012, 287, 8598-8612
17. Yu, L. L.; Wu, J. G.; Dai, N.; Yu, H. G.; Si, J. M. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-κB transcription factor Oncol. Rep. 2011, 26, 1197-1203
18. Thangapazham, R. L.; Sharma, A.; Maheshwari, R. K. Multiple molecular targets in cancer chemoprevention by curcumin AAPS J. 2012, 8, E443-E449
19. Kim, S. R.; Park, H. J.; Bae, Y. H.; Ahn, S. C.; Wee, H. J.; Yun, I.; Jang, H. O.; Bae, M. K.; Bae, S. K. Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion Endocrinology 2012, 15, 554-563
20. Aggarwal, B. B.; Shishodia, S.; Takada, Y.; Banerjee, S.; Newman, R. A.; Bueso-Ramos, C. E.; Price, J. E. Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice Clin. Cancer Res. 2005, 11, 7490-7498
21. Yu, Y.; Kanwar, S. S.; Patel, B. B.; Nautiyal, J.; Sarkar, F. H.; Majumdar, A. P. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX Transl. Oncol. 2009, 2, 321-328
22. Kunnumakkara, A. B.; Anand, P.; Aggarwal, B. B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins Cancer Lett. 2008, 269, 199-225
23. Chen, X.; Lingala, S.; Khoobyari, S.; Nolta, J.; Zern, M. A.; Wu, J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations J. Hepatol. 2011, 55, 838-845
24. Rosanò, L.; Cianfrocca, R.; Spinella, F.; Di, C. V.; Nicotra, M. R.; Lucidi, A.; Ferrandina, G.; Natali, P. G.; Bagnato, A. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells Clin. Cancer Res. 2011, 15, 2350-2360
25. Işeri, O. D.; Kars, M. D.; Arpaci, F.; Atalay, C.; Pak, I.; Gündüz, U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern Biomed. Pharmacother. 2011, 65, 40-45
26. Lee, K. Y.; Bae, S. C. TGF-β-dependent cell growth arrest and apoptosis J. Biochem. Mol. Biol. 2002, 35, 47-53
27. Biswas, S.; Guix, M.; Rinehart, C.; Dugger, T. C.; Chytil, A.; Moses, H. L.; Freeman, M. L.; Arteaga, C. L. Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression J. Clin. Invest. 2007, 117, 1305-1313
28. Minoo, P.; Li, C. Cross-talk between transforming growth factor-β and Wingless/Int pathways in lung development and disease Int. J. Biochem. Cell Biol. 2010, 42, 809-812
29. Xue, G.; Restuccia, D. F.; Lan, Q.; Hynx, D.; Dirnhofer, S.; Hess, D.; Rüegg, C.; Hemmings, B. A. AKT/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/AKT and TGF-β signaling axes Cancer Discovery 2012, 2, 248-259
30. Bandyopadhyay, A.; Wang, L.; Agyin, J.; Tang, Y.; Lin, S.; Yeh, I. T.; De, K.; Sun, L. Z. Doxorubicin in combination with a small TGFβ inhibitor: A potential novel therapy for metastatic breast cancer in mouse models PLoS One 2010, 28 e10365
31. Mittinen, P. J.; Ebner, R.; Lopez, A. R.; Derynck, R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors J. Cell Biol. 1994, 127, 2021-2036
32. Chen, X. F.; Zhang, H. J.; Wang, H. B.; Zhu, J.; Zhou, W. Y.; Zhang, H.; Zhao, M. C.; Su, J. M.; Gao, W.; Zhang, L.; Fei, K.; Zhang, H. T.; Wang, H. Y. Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways Mol. Biol. Rep. 2012, 39, 3549-3546